COMPANY

Aura Biosciences

HQ: Boston, MA source · aurabiosciences.com ↗ · New England

6 open jobs · last seen Oct 23, 2026 · 11 sources

Aura Biosciences is a clinical-stage biotechnology company leveraging a targeted oncology technology to develop a potentially therapy for patients with ocular cancers. From company website Source · Oct 12, 2026

Keywords: oncology Choroidal Melanoma Indeterminate Lesions Uveal Melanoma Ocular Melanoma Eye Cancer Primary Cancer Non-muscle-invasive Bladder Cancer NMIBC Non-Muscle Invasive Bladder Carcinoma Non-Muscle Invasive Bladder Neoplasms Non-Muscle Invasive Bladder Urothelial Carcinoma Urothelial Carcinoma Bladder Indeterminate Lesions of Eye AU-011 Light-activated AU-011

Profile checked Oct 10, 2026

6Open jobs $374.4MRaised (2 yrs)9Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
Clinical Scientist, Contractor	London, City of, United Kingdom	Not stated	Oct 23, 2026
Senior Manager, Trial Master File (TMF)	Brighton, Massachusetts	Not stated	Oct 11, 2026
(Sr) Associate Scientist, Analytical Development	Brighton, Massachusetts	Not stated	Oct 11, 2026
Executive Director, Clinical Quality Assurance	Brighton, Massachusetts	Not stated	Oct 11, 2026
Executive Director, Product Quality	Brighton, Massachusetts	Not stated	Oct 11, 2026

See all 6 jobs

Timeline

May 5, 2026 Raise Follow-on offering: $299.4M (total, as published), announced May 5, 2026. Source: company release on GlobeNewswire. source ↗
Mar 27, 2026 Trial start —: A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma source ↗
Nov 12, 2025 Trial start —: Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects source ↗
May 15, 2025 Raise Follow-on offering: $75M (total, as published), announced May 15, 2025. Source: company release on GlobeNewswire. source ↗
Dec 16, 2024 Trial start Phase 2: Suprachoroidal Administration in Subjects With Metastases to the Choroid source ↗
Dec 6, 2023 Trial start 3: A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions o source ↗
Sep 26, 2022 Trial start 1: A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer source ↗
Apr 14, 2022 Trial start —: Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM) source ↗
Aug 5, 2020 Trial start 2: Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma source ↗
Mar 27, 2019 Trial start —: A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma source ↗
Feb 27, 2017 Trial start Phase 1/Phase 2: Study in Subjects With Small Primary Choroidal Melanoma source ↗

Upcoming milestones

Nov 30, 2026 (ESTIMATED) · Phase 2 · Suprachoroidal Administration in Subjects With Metastases to the Choroid · NCT06643884
2027-03 (ESTIMATED) · 1 · A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer · NCT05483868
Nov 15, 2027 (ESTIMATED) · 3 · A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or S · NCT06007690
Aug 15, 2028 (ESTIMATED) · · Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects · NCT07421739
2028-12 (ESTIMATED) · · A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma · NCT03941379
Aug 15, 2033 (ESTIMATED) · · A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma · NCT07338968

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $374.4M. Last 2 years.

May 5, 2026 Follow-on offering: $299.4M (total, as published), announced May 5, 2026. Source: company release on GlobeNewswire. source ↗
May 15, 2025 Follow-on offering: $75M (total, as published), announced May 15, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT06643884	Suprachoroidal Administration in Subjects With Metastases to the Choroid	Phase 2	Recruiting	Dec 16, 2024	Nov 30, 2026 (estimated)
NCT07338968	A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma	Not listed	Enrolling by invitation	Mar 27, 2026	Aug 15, 2033 (estimated)
NCT05483868	A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer	1	Active, not recruiting	Sep 26, 2022	2027-03 (estimated)
NCT06007690	A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma	3	Active, not recruiting	Dec 6, 2023	Nov 15, 2027 (estimated)
NCT03941379	A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma	Not listed	Active, not recruiting	Mar 27, 2019	2028-12 (estimated)
NCT07421739	Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects	Not listed	Recruiting	Nov 12, 2025	Aug 15, 2028 (estimated)
NCT04417530	Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma	2	Completed	Aug 5, 2020	Apr 22, 2024 (actual)
NCT03052127	Study in Subjects With Small Primary Choroidal Melanoma	Phase 1/Phase 2	Completed	Feb 27, 2017	Jan 26, 2021 (actual)
NCT05266430	Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)	Not listed	Terminated	Apr 14, 2022	Feb 1, 2023 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗

Open jobs 6

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Clinical Scientist, Contractor	London, City of, United Kingdom	Not stated	Oct 23, 2026	Not stated
Senior Manager, Trial Master File (TMF)	Brighton, Massachusetts	Not stated	Oct 11, 2026	Senior
(Sr) Associate Scientist, Analytical Development	Brighton, Massachusetts	Not stated	Oct 11, 2026	Mid
Executive Director, Clinical Quality Assurance	Brighton, Massachusetts	Not stated	Oct 11, 2026	Executive
Executive Director, Product Quality	Brighton, Massachusetts	Not stated	Oct 11, 2026	Executive
Associate Director, Synthetic Organic Chemist, MSAT	Brighton, Massachusetts	Not stated	Oct 11, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Aura Biosciences on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18